
Owens & Minor (OMI) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Owens & Minor in November 2026.
Owens & Minor, Inc. is a global healthcare solutions company providing essential products and services that support care from the hospital to the home. The Company operates through two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment includes its United States distribution division (Medical Distribution), including an outsourced logistics and value-added services business, and its Global Products division, which manufactures and sources medical surgical products through its production and kitting operations. It provides medical supplies and solutions for infection prevention across acute, alternate site and consumer channels. The Patient Direct segment includes its home healthcare divisions (Byram and Apria). The segment provides delivery of disposable medical supplies sold directly to patients and home health agencies and is a provider of integrated home healthcare equipment and related services in the United States.
Owens & Minor (OMI) Stock Forecast
Analyst price target, next 12 months
$5.64
+105.1% vs today's $2.75
Price range over the last 12 months
Close to its 12-month low
Analysts covering Owens & Minor have a consensus 12-month target of $5.64, above the current price of $2.75.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 28 Nov 2025.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Owens & Minor's stock, indicating it may not rise significantly soon.
Financial Health
Owens & Minor is doing well with strong revenue and cash flow, indicating good financial stability.
Dividend
Owens & Minor Inc does not pay a dividend, which can be common as companies may reinvest profits to grow faster. If you invested $1000 you would be paid $0 a year in dividends (based on the last 12 months).
Baskets Featuring OMI
US Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketWhy invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.